Have Botanix bypassed the phase 1 trial for BTX 1801? It looks as though we are headed straight to phase 2. I’m interested to see study design and also an estimation of market sales for leading products targeting MRSA and Staph.
Ann: Botanix Initiates BTX 1702 Rosacea Study, page-15
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
28.8¢ |
Change
0.008(2.68%) |
Mkt cap ! $448.9M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.0¢ | 28.5¢ | $583.9K | 2.005M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 275203 | 28.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.0¢ | 140148 | 10 |
View Market Depth
| Last trade - 11.29am 22/05/2024 (20 minute delay) ? |
|
|||||
|
Last
28.5¢ |
Change
0.008 ( 1.86 %) |
||||
| Open | High | Low | Volume | ||
| 29.5¢ | 30.0¢ | 28.5¢ | 676180 | ||
| Last updated 11.31am 22/05/2024 ? | |||||
| BOT (ASX) Chart |